Symptoms and signs

electroCore Announces Publication in PharmacoEconomics Reiterating Economic Benefits of gammaCore for Cluster Headache Outlined by The National Institute for Health and Care Excellence (NICE) Medical Technologies Guidance

Retrieved on: 
Wednesday, August 4, 2021
Headaches, Symptoms and signs, Branches of biology, Medicine, Trigeminal autonomic cephalgia, Migraine, Cluster headache, Hemicrania continua, Headache, Medication overuse headache, International Classification of Headache Disorders

The paper is part of a series that provides insight into the development of UK National Institute for Health and Care Excellence (NICE) medical technologies guidance for new or innovative medical devices or diagnostics.

Key Points: 
  • The paper is part of a series that provides insight into the development of UK National Institute for Health and Care Excellence (NICE) medical technologies guidance for new or innovative medical devices or diagnostics.
  • The aim of the guidance is to support the adoption of clinically effective and cost-saving technologies in the UK National Health Service.
  • PharmacoEconomics reiterating the evidence supporting gammaCores effectiveness and economic benefit provides further support that gammaCore can play an important role in providing value-based therapy commented Iain Strickland, VP Global Sales and Strategy of electroCore.
  • gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

Hybrid/Virtual/Decentralized Clinical Trials Market Outlook Report 2021: Hybrid Trial Use and Experience, Provider Selection, Provider Perceptions, Future Predictions, Study Data - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Nervous system, Branches of biology, Symptoms and signs, Acute pain, Nociception, Pain, Suffering

The industry had no choice but to adapt to maintain any sort of momentum on clinical development activities.

Key Points: 
  • The industry had no choice but to adapt to maintain any sort of momentum on clinical development activities.
  • The publisher surveyed 109 respondents at sponsors and CROs regarding their experiences with hybrid trials and providers of these services.
  • Though not all reported a smooth, pain-free experience, nearly two-thirds of respondents came away with a positive overall impression of hybrid trials.
  • 83% of respondents expect that the hybrid trial model will be used more frequently than the traditional trial model three years from now.

Cymbiotika Delivers the Ultimate Pain Balm

Retrieved on: 
Wednesday, August 4, 2021
Other Health, Men, Online Retail, Specialty, Consumer, Cosmetics, Fitness & Nutrition, Retail, Women, Seniors, Alternative Medicine, Health, Nervous system, Branches of biology, Symptoms and signs, Balm, Pain

Cymbiotika , a leading nutritional supplement brand known for creating pure, clinically backed supplements, launched its Ultimate Pain Balm today.

Key Points: 
  • Cymbiotika , a leading nutritional supplement brand known for creating pure, clinically backed supplements, launched its Ultimate Pain Balm today.
  • View the full release here: https://www.businesswire.com/news/home/20210804005742/en/
    Cymbiotika's Ultimate Pain Balm penetrates deep below the skin's surface to relax and warm the muscles while reducing inflammation.
  • (Photo: Business Wire)
    Cymbiotikas Ultimate Pain Balm is infused with powerful plant compounds and plant stem cells that soothe aches and pains.
  • Ultimate Pain Balm is a fast-acting formula that stimulates blood flow and increases circulation which assists in healing and gives long-lasting relief and comfort, said Chervin Jafarieh, founder of Cymbiotika.

SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study

Retrieved on: 
Monday, August 2, 2021
Nervous system, Branches of biology, Symptoms and signs, Acute pain, Pain, Nociception, Palliative care, Peripheral neuropathy, Neuropathic pain

The study, "An evaluation of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and post-surgical pain in the rat hind paw incision model," was designed to help assess the potential of SCI-160, the Company's proprietary compound.

Key Points: 
  • The study, "An evaluation of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and post-surgical pain in the rat hind paw incision model," was designed to help assess the potential of SCI-160, the Company's proprietary compound.
  • Dr. Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, commented, "We are thrilled by this report; the findings corroborate results of previous SCI-160 pre-clinical studies.
  • The global postoperative pain management market is expected to account for $45 billion by 2026.
  • In the first study, neuropathic pain reversal experiments, injections were administered on Day 7 after nerve injury.

Lexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update

Retrieved on: 
Friday, July 30, 2021
Nervous system, Branches of biology, Symptoms and signs, Pain, Neuropathic pain, Peripheral neuropathy, Lexicon Pharmaceuticals, DPN

THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2021 and provided an update on key milestones.

Key Points: 
  • THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2021 and provided an update on key milestones.
  • We now expect to have top-line results from these studies in the first half of 2022.
  • Patient enrollment continued in RELIEF-DPN-1, a Phase 2 clinical study of LX9211 for the treatment of diabetic peripheral neuropathic pain.
  • Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Branded Legacy, Inc. Launches New Delta 8 Product Line

Retrieved on: 
Wednesday, July 28, 2021
Nervous system, Branches of biology, Symptoms and signs, Acute pain, Nociception, Pain, Suffering

The Company adds the highly demanded Delta 8 products to its portfolio under Spikes CBDX brand.

Key Points: 
  • The Company adds the highly demanded Delta 8 products to its portfolio under Spikes CBDX brand.
  • Branded Legacys Vice President, Matthew Nichols quotes, Many of the retailers our sales team has contacted have requested Delta 8, and now we can fulfill this demand.
  • About Spikes CBDx: Spikes CBDx is a line of CBD products designed to assist athletes perform better, recover faster, and avoid injuries.
  • The CBD line also targets individuals who are looking for pain relief, better sleep, faster recovery and lowering inflammation.

Steven P. Cohen, Chief of Pain Medicine at Johns Hopkins, Joins Releviate Therapeutics as Head of Its Scientific Advisory Board

Retrieved on: 
Tuesday, July 27, 2021
Professional services, Health, Venture capital, Research, Science, Pharmaceutical, Biotechnology, Nervous system, Branches of biology, Symptoms and signs, Nociception, Neuropathic pain, Pain

As head of the scientific advisory board, Cohen will provide high-level scientific oversight and lead strategy on the companys therapeutic pipeline and clinical trials.

Key Points: 
  • As head of the scientific advisory board, Cohen will provide high-level scientific oversight and lead strategy on the companys therapeutic pipeline and clinical trials.
  • View the full release here: https://www.businesswire.com/news/home/20210727005141/en/
    Dr. Steven P. Cohen joins Releviate Therapeutics as head of its scientific advisory board.
  • We are honored to welcome Steven to our scientific advisory board, said Jacqueline Townsend Konstanturos, chairman of Releviate Therapeutics.
  • Unlike traditional neuropathic pain medication strategies, Releviate Therapeutics directly targets pain with antibodies whose development is rooted in actual pain pathophysiology.

electroCore Announces Issuance of New Patent for Migraine Treatment using Smartphones

Retrieved on: 
Tuesday, July 27, 2021
Headaches, Medicine, Branches of biology, Symptoms and signs, Pain management, Neurological disorders, Migraine, Cluster headache, Headache, ElectroCore, Electrotherapy, Migraine treatment

11,065,444 to electroCore, relating to the use of a mobile phone for stimulating the trigeminal nerve to treat disorders.

Key Points: 
  • 11,065,444 to electroCore, relating to the use of a mobile phone for stimulating the trigeminal nerve to treat disorders.
  • One or more electrodes apply electrical impulses through the patient's skin modulating a targeted nerve to treat the medical condition.
  • This newly allowed patent is owned by electroCore and is the latest U.S. patent to issue in connection with the companys non-invasive development program for pain.
  • The company's current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

Q-State Biosciences Awarded NIH Grant for the Development of ASO Therapies Targeting Cancer Pain

Retrieved on: 
Tuesday, July 20, 2021
Biotechnology, Pharmaceutical, Health, Branches of biology, Nervous system, Pain, Sodium channels, Symptoms and signs, Nociception, Acute pain, Cancer pain, Oncology, National Institutes of Health, Nav1.7, Opioid

Q-State Biosciences (“Q-State”), a discovery technology and therapeutics company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system, today announced it has been awarded a non-dilutive grant of $1.3 million from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the development of antisense oligonucleotide (ASO) therapeutics for the treatment of cancer pain. Q-State will subsequently be eligible for an additional $1 million in grant funding based on successful completion of certain program milestones.

Key Points: 
  • Funded as part of the NIH HEAL InitiativeSM, the grant supports Q-States efforts to pursue analgesic treatment paradigms beyond those associated with opioids.
  • The company is currently advancing ASO candidates targeting Nav1.7, Nav1.8, or both channels using the companys AI-enabled computational neuroscience technology.
  • In addition to cancer pain, these ASO candidates also have potential applicability in the treatment of a variety of other moderate-to-severe pain states.
  • This grant was awarded by the National Institute of Cancer of the National Institutes of Health under Award Number R44CA247110.

Global Postoperative Pain Market to 2030 - Insight, Epidemiology and Market Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Health, Pharmaceutical, Nervous system, Branches of biology, Symptoms and signs, Nociception, Acute pain, Pain, Suffering

The "Postoperative Pain- Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Postoperative Pain- Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Postoperative Pain, historical and forecasted epidemiology as well as the Postoperative Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Postoperative Pain market report provides current treatment practices, emerging drugs, Postoperative Pain market share of the individual therapies, current and forecasted Postoperative Pain market Size from 2017 to 2030 segmented by seven major markets.
  • The Report also covers current Postoperative Pain treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.